Follow discharge medicines work beyond the send button.

A comparison between hospitals or pharmacies is tempting, but numbers can reflect different referral populations, recording practices and local arrangements. We would begin with one agreed pathway and establish what each stage means. Which referrals are in scope? What counts as received, acted on or completed? When is an exclusion legitimate? Answering these questions prevents a missing record from being presented as a service failure and stops a convenient denominator from creating a misleading impression of performance.

Two proportions answer different questions: actioned referrals divided by referrals received, and completed service episodes divided by the agreed eligible, linkable referral cohort. A pathway should not quietly switch between these denominators. Record a separate unknown or unlinked group, and distinguish referrals that have had enough follow-up time from those still progressing. A team can then see whether the apparent gap concerns transmission, action, completion or simply information that is not yet available.

An exploratory scan could start with permitted aggregate counts, definitions, pathway documents and staff descriptions of exceptions. Patient-level material is not needed simply to establish whether organisations use compatible stage definitions. Counts should include the reporting period and coverage. Explain where stages cannot be linked or where reporting is incomplete. This approach gives the team a useful first analysis while allowing it to decide whether a more detailed evaluation is justified and what access would be required.

A bounded PHARMORIS evaluation could compare the team's existing service-review pack with a prepared, source-linked pathway brief. Reviewers would test whether the brief correctly identifies missing stages, denominator problems and ownership questions. Inputs and the rubric would be agreed in advance. The exercise would evaluate analysis quality and preparation burden, not delivery of the clinical service. The original Commissioner Value Scan is a proposed programme direction; it is not evidence of a commissioned pilot, an accepted contract or realised benefit.

Stop if stage definitions cannot be reconciled, coverage is too incomplete to support the intended comparison or a draft presents an unsupported clinical outcome. Stop also if the preparation and checking effort exceed the value of the existing review process. A useful result may be that the pathway needs better recording before further analysis. That finding can redirect investment towards the actual constraint. Any later claim of reduced readmissions or cost would need an appropriate design, suitable data and independent clinical interpretation.

The right discussion brings hospital discharge pharmacy, community pharmacy representation and the commissioner or service owner into the same frame. Start with the question the next review meeting needs to resolve. We can discuss whether an aggregate scan is feasible, what a fair comparator looks like and what decision its findings could change. The purpose is to earn a focused evidence programme around a recognisable problem, with a clear option to stop if the information cannot support a useful conclusion.